PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
62.09
+1.02 (1.67%)
At close: Oct 27, 2026, 4:00 PM EDT
61.43
-0.66 (-1.06%)
Pre-market: Oct 28, 2026, 5:07 AM EDT
PTC Therapeutics Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, PTC Therapeutics stock has a consensus rating of "Buy" and an average price target of $97.81. The average 1-year stock price forecast is 57.53% higher than the current stock price, while the lowest is $62 (-0.14%) and the highest is $137 (+120.65%).
Price Target: $97.81 (+57.53%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for PTC Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 8 | 9 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 2 | 2 | 2 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 14 | 14 | 14 | 14 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $108 → $106 | Buy | Maintains | $108 → $106 | +70.72% | Oct 20, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $109 | Buy | Reiterates | $109 | +75.55% | Oct 18, 2026 |
| Truist Financial No rating | Truist Financial | Hold Initiates $62 | Hold | Initiates | $62 | -0.14% | Oct 16, 2026 |
| UBS | UBS | Buy Initiates $80 → $90 | Buy | Initiates | $80 → $90 | +44.95% | Oct 14, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 14, 2026 |
Financial Forecast
Revenue This Year
1.26B
from 1.73B
Decreased by -27.35%
Revenue Next Year
1.38B
from 1.26B
Increased by 9.52%
EPS This Year
1.52
from 7.62
Decreased by -80.10%
EPS Next Year
2.37
from 1.52
Increased by 56.26%
EPS and Forward PE are based on non-GAAP adjusted numbers.